Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma

Zolbetuximab (Vyloy, Astellas) in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for 'the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive'.

The dosage schedule is available in the summary of product characteristics for zolbetuximab.

The list price of zolbetuximab is £410 per 100-mg vial (excluding VAT; company submission).

The company has a commercial arrangement, which would have applied if zolbetuximab had been recommended.